Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

D S Hong, T M Bauer, J J Lee, A Dowlati, M S Brose, A F Farago, M Taylor, A T Shaw, S Montez, F Meric-Bernstam, S Smith, B B Tuch, K Ebata, S Cruickshank, M C Cox, H A Burris 3rd, R C Doebele, D S Hong, T M Bauer, J J Lee, A Dowlati, M S Brose, A F Farago, M Taylor, A T Shaw, S Montez, F Meric-Bernstam, S Smith, B B Tuch, K Ebata, S Cruickshank, M C Cox, H A Burris 3rd, R C Doebele

Abstract

Background: NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours harbouring NTRK gene fusions.

Patients and methods: This multi-centre, phase I dose escalation study enrolled adults with metastatic solid tumours, regardless of NTRK gene fusion status. Key inclusion criteria included evaluable and/or measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Larotrectinib was administered orally once or twice daily, on a continuous 28-day schedule, in increasing dose levels according to a standard 3 + 3 dose escalation scheme. The primary end point was the safety of larotrectinib, including dose-limiting toxicity.

Results: Seventy patients (8 with tumours with NTRK gene fusions; 62 with tumours without a documented NTRK gene fusion) were enrolled to 6 dose cohorts. There were four dose-limiting toxicities; none led to study drug discontinuation. The maximum tolerated dose was not reached. Larotrectinib-related adverse events were predominantly grade 1; none were grade 4 or 5. The most common grade 3 larotrectinib-related adverse event was anaemia [4 (6%) of 70 patients]. A dose of 100 mg twice daily was recommended for phase II studies based on tolerability and antitumour activity. In patients with evaluable TRK fusion cancer, the objective response rate by independent review was 100% (eight of the eight patients). Eight (12%) of the 67 assessable patients overall had an objective response by investigator assessment. Median duration of response was not reached. Larotrectinib had limited activity in tumours with NTRK mutations or amplifications. Pharmacokinetic analysis showed exposure was generally proportional to administered dose.

Conclusions: Larotrectinib was well tolerated, demonstrated activity in all patients with tumours harbouring NTRK gene fusions, and represents a new treatment option for such patients.

Clincaltrials.gov number: NCT02122913.

Keywords: NTRK gene fusion; TRK fusion cancer; adult; larotrectinib; phase I.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Figures

Figure 1.
Figure 1.
Independent review committee assessment of response in patients with TRK fusion cancer. (A) Waterfall plot of maximum percentage change in tumour size of target lesions in patients with TRK fusion cancer. Outcome for one patient with a complete response is not shown as the independent review committee assessed this patient as having non-measurable disease at baseline. (B) Swimmer plot showing time on treatment and timing of objective response for patients with tumours harbouring NTRK gene fusions.

References

    1. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169(2): 107–114.
    1. Rubin JB, Segal RA.. Growth, survival and migration: the Trk to cancer. Cancer Treat Res 2003; 115: 1–18.
    1. Amatu A, Sartore-Bianchi A, Siena S.. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1(2): e000023..
    1. Vaishnavi A, Le AT, Doebele RC.. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5(1): 25–34.
    1. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH.. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000; 24(7): 937–946.
    1. Knezevich SR, Garnett MJ, Pysher TJ. et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998; 58(22): 5046–5048.
    1. Prasad ML, Vyas M, Horne MJ. et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016; 122(7): 1097–1107.
    1. Tognon C, Knezevich SR, Huntsman D. et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2(5): 367–376.
    1. Skalova A, Vanecek T, Sima R. et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34: 599–608.
    1. Hechtman JF, Benayed R, Hyman DM. et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 2017; 41(11): 1547–1551.
    1. Lezcano C, Shoushtari AN, Ariyan C. et al. Primary and metastatic melanoma with NTRK fusions. Am J Surg Pathol 2018; 42(8): 1052–1058.
    1. Ross J, Chung J, Elvin J. et al. Abstract P2-09-15: NTRK fusions in breast cancer: clinical, pathologic and genomic findings. Cancer Res 2018; 78 (Suppl 4): abstract P2-09-15.
    1. Vaishnavi A, Capelletti M, Le AT. et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013; 19(11): 1469–1472.
    1. Drilon A, Laetsch TW, Kummar S. et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med 2018; 378(8): 731–739.
    1. Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247.
    1. Doebele RC, Davis LE, Vaishnavi A. et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 2015; 5(10): 1049–1057.
    1. Nanda N, Fennell T, Low J.. Identification of tropomyosin kinase receptor (TRK) mutations in cancer. J Clin Oncol 2015; 33(Suppl 15): abstract 1553.
    1. Laetsch TW, DuBois SG, Mascarenhas L. et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018; 19(5): 705–714.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit